![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Phase IIIb, open-label, single-arm trial of darunavir/cobicistat: Week 48 subgroup analysis of HIV-1-infected, treatment-naïve adults - PK/virology/safety/tolerability
|
|
|
Reported by Jules Levin
Presented at the 12th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2-6 November, 2014
Karen Tashima,1 Gordon Crofoot,2 Frank L Tomaka,3 Thomas N Kakuda,3 Anne Brochot,4 Simon Vanveggel,5 Magda Opsomer,5 William Garner,6
Nicolas Margot,6 Joseph M Custodio,6 Marshall W Fordyce,6 Javier Szwarcberg6
1The Miriam Hospital, Providence, RI, USA; 2Gordon Crofoot Research, Houston, TX, USA; 3Janssen Research & Development LLC, Titusville, NJ, USA; 4Janssen Research & Development, Beerse, Belgium;
5Janssen Infectious Diseases BVBA, Beerse, Belgium; 6Gilead Sciences, Foster City, CA, USA
![Glasgow1.gif](../images/111814/111814-2/Glasgow1.gif)
![Glasgow2.gif](../images/111814/111814-2/Glasgow2.gif)
![Glasgow3.gif](../images/111814/111814-2/Glasgow3.gif)
![Glasgow4.gif](../images/111814/111814-2/Glasgow4.gif)
![Glasgow5.gif](../images/111814/111814-2/Glasgow5.gif)
![Glasgow6.gif](../images/111814/111814-2/Glasgow6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|